Vitamin D3 for Life

Live Enlightened

Physiology

Vitamin D, Renin-Angiotensin Signalling and Blood Pressure: Full Study

Previous related pageVitamin D, Renin-Angiotensin Signalling and Blood Pressure: Study SummaryNext related pageVitamin D and Cardiovascular Health: Mechanisms and Clinical Outcomes
Study at a glance

Can vitamin D affect hormone signals that help control blood pressure?

Renin is a kidney enzyme that starts a chain of hormone signals involved in blood pressure and fluid balance. Researchers tested whether vitamin D signals control renin in mice and cells grown in the laboratory. A separate trial tested whether vitamin D3 supplements lowered blood pressure in older people. Removing a vitamin D receptor, giving active vitamin D and giving vitamin D3 are different ways of changing vitamin D activity.

How did vitamin D signals affect renin in mice and cells?

Mice without vitamin D receptors had higher renin activity at the gene level, more of the hormone angiotensin II and higher blood pressure. Blocking this hormone system removed the pressure difference in a small experiment. Renin remained high after blood calcium was corrected, although other hormonal abnormalities remained. Active vitamin D reduced renin gene activity in mice and in engineered mouse cells containing vitamin D receptors. These results support a possible mechanism, not a supplement treatment effect in people.

Did vitamin D3 lower blood pressure in older people?

The VitDISH trial assigned 159 people aged 70 or older with raised systolic blood pressure to vitamin D3 or placebo. Systolic pressure is the top number in a blood-pressure reading. Treatment was given every three months, with follow-up for a year. Vitamin D blood levels rose, but the trial did not show a clear reduction in blood pressure or overall improvement in the measured vessel responses. Many participants already took blood-pressure medicines.

Do these findings establish vitamin D as a blood-pressure treatment?

The trial tested one schedule of treatment given at intervals in a selected older population. It did not rule out every smaller effect or directly measure renin and angiotensin II. Exploratory differences between groups taking different medicines did not establish who should receive treatment. The laboratory mechanism and the trial result can both be valid without proving the same thing. Neither establishes a supplement dose, vitamin D blood target or prevention of heart and circulation problems.

Read the full article below ↓

Vitamin D signalling can restrain renin expression in experimental systems, but that finding does not establish that vitamin D supplements lower human blood pressure. This review follows the evidence from receptor-deficient mice and cultured cells to a placebo-controlled trial in older people with isolated systolic hypertension. The comparison separates biological mechanism, treatment exposure and measured clinical response. For the shorter account, read Vitamin D, Renin-Angiotensin Signalling and Blood Pressure: Study Summary.

The mechanism and the clinical question

Renin is an enzyme released by specialised kidney cells. It initiates a hormone cascade that generates angiotensin II, which can constrict vessels and influence fluid regulation. A change in this pathway could affect pressure through several routes. The kidney physiology overview explains the renal setting; the vascular tone overview describes the resistance component of circulation. Blood pressure also depends on cardiac output, arterial properties, medicines and compensatory responses.

Three exposures must be distinguished. Removing the vitamin D receptor eliminates a signalling route. Giving calcitriol supplies the active hormone directly. Giving cholecalciferol supplies vitamin D3, which must undergo regulated metabolism. The blood marker 25-hydroxyvitamin D reflects another part of that process. These interventions cannot be treated as interchangeable doses along one simple scale. The distinction between measured status and biological effect is central to interpreting this evidence.

Li 2002: receptor deletion and renin regulation

Li and colleagues compared mice lacking the vitamin D receptor throughout the body with wild-type littermates. This was a global genetic model, not deletion confined to the kidney or heart. It also produced major mineral and hormonal abnormalities. Adult renal renin messenger RNA, a measure of gene expression, was more than three times higher in receptor-null mice. Circulating angiotensin II was more than 2.5 times higher, with 15 mice per group for that assay and P less than 0.001.

Both systolic and diastolic pressure were more than 20 mm Hg higher in the mutant group, measured through a carotid catheter under pentobarbital anaesthesia. There were nine wild-type and eight receptor-null mice in the pressure comparison. Heart weight relative to body weight was also higher. These measurements connect receptor loss with renin, angiotensin and a cardiovascular phenotype. They do not reproduce the circumstances of an awake person with a moderately low vitamin D blood result.

The investigators then gave the angiotensin-converting-enzyme inhibitor captopril in drinking water for five days, at a reported 100 mg/kg/day. In this small experiment, with four animals in each group, the pressure difference was no longer apparent after treatment. That supports involvement of the renin-angiotensin system. It does not show that every consequence of receptor deletion is mediated exclusively by renin, or that nutritional supplementation reverses the whole phenotype. The receptor overview helps distinguish loss of receptor function from altered availability of its ligand.

Minerals, salt responses and the remaining alternatives

Adult receptor-null mice had low ionised calcium and greatly elevated parathyroid hormone, or PTH. These accompanying changes could themselves alter physiology. The researchers therefore examined young mice before hypocalcaemia developed and fed adult mutants a calcium-, phosphate: and lactose-enriched rescue diet for five weeks. Renin remained elevated in normocalcaemic young mice and after dietary correction of adult blood calcium. Angiotensin II also remained elevated after the rescue diet.

This is useful evidence against low blood calcium being the complete explanation. It is less decisive about PTH: PTH was still approximately sixfold higher in young mutants and sevenfold higher after the rescue diet. The authors acknowledged that an in-vivo contribution of PTH could not be fully excluded. The broader account of calcium physiology matters here because correcting one measured mineral does not automatically normalise every endocrine consequence of receptor loss.

Salt and fluid challenges showed that feedback control had not simply disappeared. An eight-percent-salt diet suppressed renin in both genotypes, while 24-hour water deprivation increased it; mutant levels remained higher. These small challenge groups, generally three animals per condition, suggest an altered baseline with preserved responsiveness to familiar regulators. Water intake and urine output were roughly doubled in the mutants, but blood sodium and potassium were not significantly different. Increased intestinal salt absorption was an interpretation, not a directly measured transport result.

Adding active hormone and testing transcription

Wild-type mice received 30 pmol of calcitriol by intraperitoneal injection. Two doses over two days reduced renal renin messenger RNA by about 35%; five doses over three days reduced it by about 50%, with at least three animals per group. A complementary strontium-feeding experiment, intended to impair active-vitamin-D production, increased renin. However, the investigators did not directly measure calcitriol in that experiment; they used the fall in ionised calcium as evidence of disturbed vitamin D physiology. That limitation prevents treating every step as a directly observed biochemical chain.

The cell work used As4.1 cells, a mouse kidney-tumour-derived line with features of renin-producing cells. The investigators introduced human vitamin D receptor expression. Calcitriol then strongly suppressed renin messenger RNA, including an approximately 90% reduction after 24 hours at 50 nM in the transient-transfection experiment. Cells receiving the empty vector showed little suppression. A stable receptor-expressing line also responded, supporting receptor dependence within this preparation.

A reporter containing 4.1 kilobases of the mouse renin promoter lost more than 80% of its activity after calcitriol exposure, whereas a control promoter did not show the same response. This supports regulation at the transcriptional level. The exact DNA elements and molecular repression mechanism were not resolved by this paper. Engineered receptor expression in a tumour-derived cell line is a valuable test of a proposed route, with limits to how closely it reproduces normal human kidney cells.

The experiments used different small samples, commonly displayed as means with standard deviations and assessed with t tests. Their converging genetic, rescue, drug and cell comparisons strengthen the mechanistic argument, but do not make the work a clinical dose-response study. The paper’s hypothesis that vitamin D analogues might help cardiovascular disease was a proposal for testing. It was not an observed prevention outcome.

VitDISH: what was actually randomised?

Witham and colleagues tested a different question: whether oral vitamin D3 improves pressure in older people who retain their receptors. VitDISH randomised 159 community-dwelling participants in one Scottish health-board area: 80 received cholecalciferol and 79 matching placebo. Participants were at least 70 years old, all were white, and mean age was about 77. Isolated systolic hypertension means raised systolic pressure with diastolic pressure below 90 mm Hg. Mean baseline office pressure was approximately 163/78 mm Hg, and mean 25-hydroxyvitamin D was 18 ng/mL.

Eligibility required vitamin D status below 30 ng/mL and office systolic pressure above 140 mm Hg. The registered exclusions included systolic pressure above 180 mm Hg, estimated glomerular filtration rate below 40 mL/min, significant calcium abnormalities, heart failure with left-ventricular systolic dysfunction and existing vitamin D supplementation. These restrictions matter when considering other populations. The accessible registration corroborates eligibility and the primary outcome; it does not replace the unavailable supplementary eMethods or provide the detailed adverse-event eTable.

Allocation was concealed through a central telephone system, using minimisation for baseline vitamin D, systolic pressure, age and diabetes. Treatment bottles were masked, and patients were observed taking 100,000 IU of cholecalciferol or matching placebo at baseline and at three, six and nine months. Follow-up lasted one year. This was intermittent high-dose administration, not a trial of daily dosing or direct calcitriol. Median baseline use was two antihypertensive medicines; roughly half or more in each group already used renin-angiotensin-system blockers.

The prespecified primary comparison was office blood pressure at three months. The study also measured ambulatory pressure, brachial-artery flow-mediated dilatation, carotid-radial pulse-wave velocity and several biomarkers. The first vascular test measures a dilation response; the second describes pulse transmission and arterial stiffness. Neither is itself a count of heart attacks or strokes. The connection to cardiac physiology is relevant, but a physiological measurement should retain its own meaning.

Results, uncertainty and retention

Vitamin D exposure clearly changed: treated-group 25-hydroxyvitamin D rose to about 28 ng/mL by six months, with a reported net difference of about 8 ng/mL at one year. Adherence to planned administrations was high: 301 of 303 doses in the vitamin D group and 285 of 294 in the placebo group. The flow diagram shows 76 versus 74 participants attending three months, and 73 versus 69 at twelve months. Thus, treatment delivery was strong but follow-up was not complete.

The primary-results text reports an adjusted three-month systolic difference of −0.7 mm Hg, with a 95% confidence interval from −5.2 to 3.8 and P=0.76. Negative values favour vitamin D. The point estimate is small and the interval crosses zero, leaving both some reduction and some increase compatible with these data. The paper’s rounded tabular estimates are not numerically identical to that prose estimate; all support the same absence of a clear pressure-lowering effect. They should not be treated as an equivalence test.

Across follow-up, the adjusted office-pressure treatment effect was +1 mm Hg for systolic pressure, with a 95% confidence interval from −2 to 4, and 0 mm Hg for diastolic pressure, with an interval from −2 to 2. Daytime ambulatory systolic pressure also showed an overall estimate close to zero. Baseline daytime systolic values were only about 136 and 133 mm Hg in the two groups, substantially below office values, which limited the scope for lowering that particular measure.

Analysis adjusted for baseline values and minimisation factors, with additional medication adjustment and sensitivity analyses. The main analysis included participants with baseline and relevant follow-up measurements; multiple imputation examined missing-data assumptions. Excluding the few participants whose antihypertensive therapy changed did not materially alter the result. The trial was designed to detect a 7 mm Hg systolic difference, so a nonsignificant result should not be described as ruling out every smaller effect.

Secondary signals and what they do not prove

There was no overall improvement in flow-mediated dilatation or pulse-wave velocity. Their overall adjusted differences were −0.4 percentage points, with a 95% confidence interval from −1.1 to 0.4, and −0.2 m/s, with an interval from −0.5 to 0.2, respectively. Renin and angiotensin II were not reported as trial outcomes. A null pressure result therefore does not directly demonstrate that the cellular renin mechanism is absent in humans.

Nor was every statistical test null. The adjusted diastolic group-by-time interaction had P=0.03 without a consistent pressure-lowering pattern. A post hoc interaction suggested different systolic responses according to existing ACE-inhibitor or angiotensin-receptor-blocker use, with P=0.02. Because this was an exploratory subgroup analysis among several comparisons, it does not establish a treatment-responsive subgroup or justify combining a supplement with those medicines. A small walking-distance difference at six months was not sustained clearly at twelve months; these findings do not overturn the primary pressure result.

One participant in each group had an asymptomatic calcium result above 10.6 mg/dL. The main paper reported no clear excess of adverse events, but a trial of 159 people cannot exclude rare harms. The inaccessible supplementary event table limits independent appraisal of individual event categories. The Scottish Government funded the trial and the University of Dundee sponsored it; the paper states that neither controlled analysis, interpretation or manuscript approval.

How the two studies fit together

The mouse work provides experimentally supported evidence that receptor-mediated vitamin D signalling can regulate renin expression. VitDISH provides randomised evidence that this particular cholecalciferol regimen did not clearly lower blood pressure in this selected older population. These conclusions can coexist because species, receptor status, intervention, background treatment and outcome all differ. The guide to evidence hierarchies explains why mechanistic relevance and clinical efficacy require different tests.

The studies do not establish an effective supplement dose, a blood concentration target, or prevention of cardiovascular events. They also do not show that vitamin D has no biological role in circulation. The useful conclusion is specific: a plausible and experimentally supported renin mechanism is insufficient, by itself, to predict a measurable blood-pressure benefit from nutritional supplementation.

Scientific sources

Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. Journal of Clinical Investigation. 2002;110(2):229-238. DOI: 10.1172/JCI15219. PMID: 12122115. Mouse and cell experiments; complete main paper, tables and figures examined.

Witham MD, Price RJG, Struthers AD, Donnan PT, Messow CM, Ford I, McMurdo MET. Cholecalciferol Treatment to Reduce Blood Pressure in Older Patients With Isolated Systolic Hypertension: The VitDISH Randomized Controlled Trial. JAMA Internal Medicine. 2013;173(18):1672-1679. DOI: 10.1001/jamainternmed.2013.9043. PMID: 23939263. Randomised clinical trial; main paper, figures and tables examined. Supplementary eMethods and adverse-event eTable were not accessible.

University of Dundee; study investigator Miles Witham. Vitamin D for Isolated Systolic Hypertension (VitDISH). ISRCTN92186858. Registered 21 August 2008. DOI: 10.1186/ISRCTN92186858. Registration supplies prespecified outcomes and eligibility; it is a record of the same trial, not independent efficacy evidence.

Related reading

Library

Evaluating the effect of vitamin D supplementation on serum levels of 25-hydroxy vitamin D, 1,25-dihydroxy vitamin D, parathyroid hormone and renin-angiotensin-aldosterone system: a systematic review and meta-analysis of clinical trials

In this study, we aimed to evaluate the vitamin D supplements efficiency on serum levels of 25-hydroxy vitamin D (25(OH)D), 1,25-dihdroxy vitamin D (1,25(OH)2D), parathyroid hormone (PTH) and renin: angiotensin: aldosterone system (RAAS) in adults.

Original paper ↗Read more →

Original sources

Source

Cholecalciferol Treatment to Reduce Blood Pressure in Older Patients With Isolated Systolic Hypertension: The VitDISH Randomized Controlled Trial

Published in JAMA Internal Medicine (2013).

Publication details

Witham MD, Price RJG, Struthers AD, Donnan PT, Messow CM, Ford I, McMurdo MET. Cholecalciferol Treatment to Reduce Blood Pressure in Older Patients With Isolated Systolic Hypertension: The VitDISH Randomized Controlled Trial. JAMA Internal Medicine. 2013;173(18):1672-1679. DOI: 10.1001/jamainternmed.2013.9043. PMID: 23939263. Randomised clinical trial; main paper, figures and tables examined. Supplementary eMethods and adverse-event eTable were not accessible.

Read more →
Source

Vitamin D for Isolated Systolic Hypertension (VitDISH)

University of Dundee; study investigator Miles Witham.

Publication details

University of Dundee; study investigator Miles Witham. Vitamin D for Isolated Systolic Hypertension (VitDISH). ISRCTN92186858. Registered 21 August 2008. DOI: 10.1186/ISRCTN92186858. Registration supplies prespecified outcomes and eligibility; it is a record of the same trial, not independent efficacy evidence.

Read more →